Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$132MCash on Hand
13.3mo Cash Runway
Follow IMUX by emailGet an email when IMUX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about IMUX, unsubscribe in one click. Privacy
📣 What IMUX Says Is Next
in December 2026 · vidofludimus calcium: “The company’s lead investigational asset , vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials in relapsing multiple sclerosis, with top-line data expected to be available in December 2026.”
Company press release, Nov 13, 2026 · SEC filing
first half of 2027 · vidofludimus calcium: “Vidofludimus Calcium in Progressive MS: The initiation of the Phase 3 PROTECT-MS trial in progressive MS is ongoing, with first-patient-enrolled expected in the first half of 2027.”
Company press release, Nov 13, 2026 · SEC filing
mid-2027 · vidofludimus calcium: “If positive, Immunic plans to submit an NDA in the United States in mid-2027, with a targeted potential regulatory approval date in 2028.”
Company press release, Nov 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 13, 2026 ·
Earnings Reported third quarter 2026 results and a corporate update. Top-line Phase 3 ENSURE-1 and ENSURE-2 data in relapsing MS remain on track for December 2026. Appointed Jaa Roberson as Chief People Officer and Chitrang Davé as Chief Data and Digital Officer. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Immunic will host a Progressive Multiple Sclerosis R&D Day webinar on November 5, 2026, from 12:30 p.m. to 2:00 p.m. ET, using a presentation furnished as Exhibit 99.1. Form 8-K · SEC filing · Press release
Sep 11, 2026 ·
Leadership Director Dr. Duane Nash resigned from the board on September 10, 2026, not due to any disagreement with the company. The board was reduced from ten members to nine. Form 8-K · SEC filing
Sep 9, 2026 ·
Immunic will host a Relapsing Multiple Sclerosis R&D Day webinar on September 9, 2026, from 11:00 a.m. to 12:30 p.m. ET, using a presentation furnished as Exhibit 99.1. Form 8-K · SEC filing · Press release
Aug 11, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Aug 11, 2026 ·
Leadership Elena Ridloff, CFA, was appointed to the Board of Directors effective August 6, 2026, as a Class I director, with a grant of options to purchase 50,740 shares. The filing also reports the resignation of Dr. Daniel Vitt on August 6, 2026, and the company's Q2 2026 results. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Nov 2026 · Phase 3 · Active Trial · Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis Registry date passed, readout not confirmed
Nov 2026 · Phase 3 · Active Trial · Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis Registry date passed, readout not confirmed
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
IMUX holds $132M in cash and short-term investments (as of Sep 30, 2026) and burns about $29.7M/quarter from operations,
an estimated runway of 13.3 months at that rate (BioRadar estimate, not company guidance).
Share count 15,880,822 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full IMUX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMUX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.